Altimmune, Inc. (ALT)
3.36
-0.06
(-1.75%)
USD |
NASDAQ |
Mar 20, 16:00
3.40
+0.04
(+1.19%)
Pre-Market: 20:00
Altimmune Research and Development Expense (Quarterly) : 18.38M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.802B |
| CorMedix, Inc. | 8.60M |
| Amgen, Inc. | 2.151B |
| Viking Therapeutics, Inc. | 153.46M |
| Verastem, Inc. | 31.68M |